These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11004672)

  • 1. TP53 mutations and MDM2 gene amplification in squamous-cell carcinomas of the esophagus in south Thailand.
    Tanière P; Martel-Planche G; Puttawibul P; Casson A; Montesano R; Chanvitan A; Hainaut P
    Int J Cancer; 2000 Oct; 88(2):223-7. PubMed ID: 11004672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.
    Tanière P; Martel-Planche G; Saurin JC; Lombard-Bohas C; Berger F; Scoazec JY; Hainaut P
    Br J Cancer; 2001 Sep; 85(5):721-6. PubMed ID: 11531258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran.
    Sepehr A; Tanière P; Martel-Planche G; Zia'ee AA; Rastgar-Jazii F; Yazdanbod M; Etemad-Moghadam G; Kamangar F; Saidi F; Hainaut P
    Oncogene; 2001 Nov; 20(50):7368-74. PubMed ID: 11704866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
    Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
    Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
    Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
    J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.
    Hollstein MC; Peri L; Mandard AM; Welsh JA; Montesano R; Metcalf RA; Bak M; Harris CC
    Cancer Res; 1991 Aug; 51(15):4102-6. PubMed ID: 1855226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.
    Ahomadegbe JC; Barrois M; Fogel S; Le Bihan ML; Douc-Rasy S; Duvillard P; Armand JP; Riou G
    Oncogene; 1995 Mar; 10(6):1217-27. PubMed ID: 7700647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
    Waber PG; Chen J; Nisen PD
    Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutational spectrum of esophageal carcinomas from five different geographical locales in China.
    Lung ML; Chan WC; Zong YS; Tang CM; Fok CL; Wong KT; Chan LK; Lau KW
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):277-84. PubMed ID: 8722219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 overexpression in squamous cell carcinoma of the esophagus.
    Baron PL; Gates CE; Reed CE; Dikeman RL; Drosieko JJ; Passmore RN; Bromberg JS; Willingham MC
    Ann Surg Oncol; 1997 Jan; 4(1):37-45. PubMed ID: 8985516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history.
    Bennett WP; von Brevern MC; Zhu SM; Bartsch H; Muehlbauer KR; Hollstein MC
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):963-6. PubMed ID: 9367071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of p53 mutations and protein expression in esophageal cancers in southern Thailand.
    Suwiwat S; Oda H; Shimizu Y; Ishikawa T
    Int J Cancer; 1997 Jul; 72(1):23-6. PubMed ID: 9212217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
    Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
    J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas.
    Esteve A; Lehman T; Jiang W; Weinstein IB; Harris CC; Ruol A; Peracchia A; Montesano R; Hollstein M
    Mol Carcinog; 1993; 8(4):306-11. PubMed ID: 8280379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations in esophageal tumors from high-incidence areas of China.
    Liang YY; Estève A; Martel-Planche G; Takahashi S; Lu SH; Montesano R; Hollstein M
    Int J Cancer; 1995 May; 61(5):611-4. PubMed ID: 7768632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas.
    Ohnishi H; Kawamura M; Hanada R; Kaneko Y; Tsunoda Y; Hongo T; Bessho F; Yokomori K; Hayashi Y
    Genes Chromosomes Cancer; 1996 Mar; 15(3):187-90. PubMed ID: 8721685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.